Two linked randomized trials published in JAMA support a role for verapamil, but not for intensive glycemic control, to slow C-peptide decline in children with newly diagnosed type 1 diabetes.
A multifaceted, clinic-level intervention results in a marked increase in the proportion of people with type 2 diabetes and atherosclerotic cardiovascular disease receiving appropriate medications, shows the COORDINATE randomized trial.
Use of intermittently scanned continuous glucose monitoring is associated with an increased likelihood for treatment intensification in people with type 2 diabetes, a study shows.
A health informatics system based on routine clinical data helps physicians to prioritize high-risk people with diabetes, deliver more equitable care, and manage healthcare capacity, report researchers.
A short period of intermittently scanned continuous glucose monitoring prior to a first endocrinologist consultation can improve glycemic outcomes for people with type 2 diabetes, report the SPOT FIRST study researchers.
People with high diabetes distress achieve reductions in glycated hemoglobin and the need for emergency care for acute diabetes complications after starting on intermittently scanned continuous glucose monitoring, report researchers.
Hypertension has the largest impact on mortality risk in younger people with type 2 diabetes, whereas chronic kidney disease is a greater threat for older people, shows a population-based study.
The benefits of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes are sustained for at least 2 years, shows the extension of the ALERTT1 study.
There is a “substantial” burden of overweight and obesity among people with type 1 diabetes, say US researchers who found rates to be in line with that of the general population.
Empagliflozin, but not linagliptin, provides “clinically relevant” improvements in glycemic control versus placebo in children and adolescents with type 2 diabetes, report the DINAMO investigators.
“Almost no one” who is islet autoantibody negative at age 10 years despite a high familial risk for type 1 diabetes will develop clinical diabetes by the age of 18, report researchers.
A randomised trial shows that use of a prebiotic fibre-enriched nutritional formula results in improved life quality and, potentially, better glycaemic control in people with type 2 diabetes.
People with type 2 diabetes who maintain low glycated haemoglobin levels have slower progression of frailty over time than those with higher levels, shows an analysis of Look AHEAD participants.
Pregnant women with type 1 diabetes can achieve similar glucose control regardless of whether they use insulin degludec or detemir, show the results of the randomised EXPECT trial.
Metformin use is associated with a significant reduction in the risk for total knee or hip replacement among people with type 2 diabetes, shows research published in CMAJ.
The incidence and burden of type 2 diabetes in young people aged 15–39 years are increasing worldwide, show data from the Global Burden of Disease Study.
Stay informed with Medicine Matters
Get the latest developments in diabetes delivered straight to your inbox